|
Name |
18-Deoxy-19,20-epoxycytochalasin Q
|
| Molecular Formula | C30H37NO6 | |
| IUPAC Name* |
[(1R,2S,3R,5S,6S,8S,10Z,13S,15R,16S,17R,18S)-18-benzyl-6,8,15,16-tetramethyl-7,20-dioxo-4,14-dioxa-19-azapentacyclo[10.8.0.01,17.03,5.013,15]icos-10-en-2-yl] acetate
|
|
| SMILES |
C[C@H]1C/C=C\C2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2([C@@H]([C@H]5[C@@H](O5)[C@@H](C1=O)C)OC(=O)C)C(=O)N[C@H]4CC6=CC=CC=C6)C)C
|
|
| InChI |
InChI=1S/C30H37NO6/c1-15-10-9-13-20-26-29(5,37-26)17(3)22-21(14-19-11-7-6-8-12-19)31-28(34)30(20,22)27(35-18(4)32)25-24(36-25)16(2)23(15)33/h6-9,11-13,15-17,20-22,24-27H,10,14H2,1-5H3,(H,31,34)/b13-9-/t15-,16+,17-,20?,21-,22-,24-,25+,26-,27+,29+,30-/m0/s1
|
|
| InChIKey |
ZVDZUUFSGNTNLH-RVIPWBFWSA-N
|
|
| Synonyms |
18-Deoxy-19,20-epoxycytochalasin Q
|
|
| CAS | NA | |
| PubChem CID | 139586853 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 507.6 | ALogp: | 3.4 |
| HBD: | 1 | HBA: | 6 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 97.5 | Aromatic Rings: | 6 |
| Heavy Atoms: | 37 | QED Weighted: | 0.377 |
| Caco-2 Permeability: | -4.814 | MDCK Permeability: | 0.00007180 |
| Pgp-inhibitor: | 0.986 | Pgp-substrate: | 0.073 |
| Human Intestinal Absorption (HIA): | 0.1 | 20% Bioavailability (F20%): | 0.135 |
| 30% Bioavailability (F30%): | 0.236 |
| Blood-Brain-Barrier Penetration (BBB): | 0.649 | Plasma Protein Binding (PPB): | 82.26% |
| Volume Distribution (VD): | 1.983 | Fu: | 12.95% |
| CYP1A2-inhibitor: | 0.032 | CYP1A2-substrate: | 0.114 |
| CYP2C19-inhibitor: | 0.073 | CYP2C19-substrate: | 0.421 |
| CYP2C9-inhibitor: | 0.104 | CYP2C9-substrate: | 0.022 |
| CYP2D6-inhibitor: | 0.015 | CYP2D6-substrate: | 0.299 |
| CYP3A4-inhibitor: | 0.865 | CYP3A4-substrate: | 0.509 |
| Clearance (CL): | 9.68 | Half-life (T1/2): | 0.765 |
| hERG Blockers: | 0.421 | Human Hepatotoxicity (H-HT): | 0.808 |
| Drug-inuced Liver Injury (DILI): | 0.956 | AMES Toxicity: | 0.032 |
| Rat Oral Acute Toxicity: | 0.564 | Maximum Recommended Daily Dose: | 0.738 |
| Skin Sensitization: | 0.256 | Carcinogencity: | 0.097 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.012 |
| Respiratory Toxicity: | 0.979 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001886 | ![]() |
0.793 | D0W7RJ | ![]() |
0.248 | ||
| ENC002828 | ![]() |
0.750 | D00OAY | ![]() |
0.247 | ||
| ENC005176 | ![]() |
0.708 | D0M6VK | ![]() |
0.244 | ||
| ENC005505 | ![]() |
0.683 | D04LHJ | ![]() |
0.243 | ||
| ENC002202 | ![]() |
0.680 | D0TB8C | ![]() |
0.242 | ||
| ENC004310 | ![]() |
0.672 | D0V3ZA | ![]() |
0.242 | ||
| ENC003763 | ![]() |
0.656 | D0D4YZ | ![]() |
0.241 | ||
| ENC005175 | ![]() |
0.656 | D0R1BD | ![]() |
0.239 | ||
| ENC005506 | ![]() |
0.656 | D07HOF | ![]() |
0.239 | ||
| ENC005546 | ![]() |
0.653 | D0D4IH | ![]() |
0.237 | ||